SAN.PA - Sanofi
| Previous Close | 83.81 |
| Open | 84.08 |
| Bid | 71.12 x 1000 |
| Ask | 71.74 x 44000 |
| Day's Range | 84.08 - 84.74 |
| 52 Week Range | 24.55 - 87.65 |
| Volume | 338,683 |
| Avg. Volume | 20,194 |
| Market Cap | 104.23B |
| Beta | 0.73 |
| PE Ratio (TTM) | 11.82 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.30 (3.40%) |
| Ex-Dividend Date | 2017-05-16 |
| 1y Target Est | N/A |
- Market Realist•3 days ago
Sanofi Stock: Performance in 3Q17
Sanofi stock has risen ~3.9% in 3Q17. It has risen 22.5% year-to-date as of October 20, 2017.
- Reuters•6 days ago
Regeneron-Sanofi drug succeeds mid-stage study
The drug, dupilumab, was statistically significant in improving the ability to swallow in adults with moderate-to-severe eosinophilic esophagitis, when compared with a placebo. Eosinophilic esophagitis is a chronic, allergic inflammatory disease that damages the pipe that connects the throat and the stomach, and can lead to food getting stuck in the oesophagus and difficulties in swallowing.
- Zacks•6 days ago
Sanofi/Regeneron's Dupixent Succeeds in Phase II Study
Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.
- Market Realist•6 days ago
Sanofi’s Consumer Healthcare Expected to Be Long-Term Driver
In 2Q17, Sanofi’s (SNY) Consumer Healthcare business reported revenues of 1.2 billion euros, which is a 42.5% YoY rise on a CER basis and a YoY fall of 0.10% on a CER and CS basis.
- Reuters•6 days ago
UPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study
Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat inflammation in the esophagus, mainly caused by food allergies, met the main goal of a mid-stage study. The drug, dupilumab, was statistically significant in improving the ability to swallow in adults with moderate-to-severe eosinophilic esophagitis, when compared with a placebo. Eosinophilic esophagitis is a chronic, allergic inflammatory disease that damages the pipe that connects the throat and the stomach, and can lead to food getting stuck in the esophagus and difficulties in swallowing.
- Market Realist•7 days ago
Vaccines Business Expected to Boost Sanofi’s Revenues in 2017
In 2Q17, Sanofi’s (SNY) vaccine business reported revenues of 1.0 billion euros, which is a YoY rise of 26.2% on a CER basis and 19.2% on a CER and CS basis.
- Reuters•7 days ago
Aimmune teams with Regeneron, Sanofi on peanut allergy drug
Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug. The company said it would test the drug, AR101, in combination with Regeneron and Sanofi's dupilumab in a mid-stage trial that is expected to start in 2018 and will be sponsored by Regeneron. AR101, an oral immunotherapy, is already being tested as a mono-therapy for peanut allergy in a late-stage trial.
- Market Realist•7 days ago
Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis
Launched in US markets in June 2017, Kevzara (sarilumab), Sanofi (SNY) and Regeneron’s (REGN) IL-6 receptor antibody, has received favorable feedback from the physician community.
- Reuters•7 days ago
Regeneron-Sanofi throat infection drug succeeds key study
Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat patients with a rare throat infection met the main goal of a mid-stage study. The drug, dupilumab, was statistically significant ...
- Investor's Business Daily•7 days ago
Regeneron Advances Science To Attack Arthritis, Eye Disease, More
Regeneron became a star with its treatment for a common eye disease, but treatments for dermatitis, arthritis, asthma and cancer could bring superstardom.
- Market Realist•7 days ago
Dupixent May Be Strong Growth Driver for Sanofi in the Future
Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).
- The Wall Street Journal•7 days ago
[$$] Warp Drive Bio, Roche Forge $387 Million Antibiotics Pact
Warp Drive Bio Inc. could wind up $387 million richer thanks to a new antibiotic drug deal struck with Roche.
- Market Realist•9 days ago
Specialty Segment Drives Sanofi’s Revenue Growth in 2017
In 2Q17, Sanofi’s (SNY) Sanofi Genzyme, its specialty care business, reported revenues of 1.7 billion euros, which is a 13.6% rise YoY (year-over-year).
- Market Realist•10 days ago
Sanofi and Its Peers: Analysts’ Recommendations in October
Of the three analysts covering Sanofi in October 2017, two have rated the stock a “strong buy,” and one has rated it a “hold.”
- Forbes•10 days ago
Big Pharma Killed The Cancer Drug He Invented. He Raised $22 Million To Revive It
“They were asking for help to get the drug back. They were dying. Most of them died. It was very motivating to try to get it back."
- Motley Fool•10 days ago
A New FDA Approval Sends Small Cap Flexion Soaring
Flexion's non-opioid pain management drug has huge potential, and it's looking to expand into more indications.
- Zacks•12 days ago
Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit
With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.
- Investor's Business Daily•13 days ago
This Biotech Hit Record High; Could Undercut Regeneron In Eczema
AnaptysBio soared Tuesday after its eczema drug appeared to outperform a potential blockbuster rival drug from Regeneron and Sanofi.
- Zacks•14 days ago
Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit
Emergent BioSolutions (EBS) announced that it has acquired FDA-licensed smallpox vaccine's business of Sanofi (SNY) ??? ACAM2000.
- Motley Fool•15 days ago
3 High-Yield Healthcare Stocks
If you're on the hunt for above-average yields, these three healthcare stocks should be on your radar.
- Investor's Business Daily•17 days ago
Why Regeneron's Patent Win Is Worse For Amgen Than You Think
Amgen's patents covering LDL cholesterol-lowering drug Repatha are likely to be invalidated, an analyst says.
- Zacks•17 days ago
Regeneron and Sanofi Get Favorable Ruling Against Amgen
Regeneron Pharmaceuticals(REGN) and partner Sanofi, Inc. (SNY) receives a favorable ruling from the Court of Appeals for the Federal Circuit relating to Praluent.
Reuters•18 days agoAt least six funds interested in Sanofi European generic drugs unit - Le Figaro
French pharmaceutical group Sanofi (SASY.PA) is set to start the process to sell its generic drug business in Europe, and at least six funds have expressed interest to investment banks mandated by group, France's Le Figaro newspaper reported. Rothschild and JP Morgan, two investment banks mandated by Sanofi to handle the divestment, will send out memos to potential buyers in the next few weeks, Le Figaro said in its Friday edition. Sources told Reuters in March that Rothschild [ROT.UL], JP Morgan (JPM.N) and Morgan Stanley (MS.N) had been asked to organise the long-awaited deal.
- Reuters•18 days ago
At least six funds interested in Sanofi European generic drugs unit -Le Figaro
French pharmaceutical group Sanofi is set to start the process to sell its generic drug business in Europe, and at least six funds have expressed interest to investment banks mandated by group, France's Le Figaro newspaper reported. Rothschild and JP Morgan, two investment banks mandated by Sanofi to handle the divestment, will send out memos to potential buyers in the next few weeks, Le Figaro said in its Friday edition. Sources told Reuters in March that Rothschild, JP Morgan and Morgan Stanley had been asked to organise the long-awaited deal.
- The Wall Street Journal•18 days ago
[$$] Appeals Court Rules Against Amgen in Patent Case
A U.S. federal appeals court said Regeneron Pharmaceuticals and partner Sanofi can continue selling their cholesterol drug, dealing a blow to rival Amgen, which had accused the companies of violating its ...
